Table 2.
Target Up (+) or Down (−) |
Method | Model | Result | Reference | |
---|---|---|---|---|---|
Drp1 (−) | Melatonin | I/R | Diabetic rat with I/R injury | Decrease in MI size and apoptosis | [175] |
Hydralazine | C57BL/6N with I/R injury | MI size reduction | [176] | ||
P110 | Wistar rat, Ex vivo | Improvement of mitochondrial morphology and mitochondrial respiratory function. | [177] | ||
Dynasore | C6/Black, Ex vivo | Increase in cardiomyocyte viability | [178] | ||
BTP2 | Diabetic CM | Zucker diabetic fat | Improvement of cardiomyocyte hypertrophy | [132] | |
Klotho | Dox-CM | C57BL/6 treated with doxorubicin | Inhibition of apoptosis | [180] | |
Sevoflurane postconditioning | Ischemic HF | Sprague-Dawley rat with I/R injury | Improvement of ATP production with mitophagy | [181] | |
Mdivi-1 | ATS | Human VSMC | Suppression of VSMC calcification | [182] | |
Melatonin | Rat VSMC | Suppression of arterial calcification | [183] | ||
Irisin | High-phosphorus-diet C57BL/6 | Suppression of arterial calcification | [184] | ||
Quercetin | Adenine-rich diet rat | Suppression of arterial calcification | [185] | ||
Mdivi-1 | HTN | C57BL/6 treated with AngII | Inhibition of AngII-mediated phenotypic switch | [186] | |
Mdivi-1 | High-salt-fed rat | Reduction of cardiac hypertrophy and fibrosis | [187] | ||
Mdivi-1 | Rat VSMC | Suppression of arterial calcification | [188] | ||
Dichlorpacetate | PH | Monocrotaline-treated rat | Inhibition of right ventricular fibrosis and hypertrophy | [189] | |
Liraglutide | Rat PASMC | Inhibition of cell proliferation | [191] | ||
ARB | Aging | Human VSMC and ApoE KO mice | Reduction of hyperlipidemic aging | [192] | |
P110 | Huntington Disease (HD) model mice | Reduction of pathological mitochondrial fission | [193] | ||
Mfn1 (+) | SAMβA | Ischemic HF | Rat treated with AngII | Inhibition of apoptosis | [194] |
Mfn2 (+) | Cordycepin | I/R | Diabetic mice with I/R injury | MI size reduction | [196] |
ARB | ATS | Rat VSMC | Inhibition of cell proliferation | [197] | |
Adiponectin | ATS | Human VSMC | Inhibition of cell proliferation | [198] | |
Mfn2 (−) | Pomegranate | HTN | SHR | Reduction of oxidative stress | [199] |
Mfn1 and Mfn2 (+) |
Aerobic exercise | I/R | Wistar rat with I/R injury | MI size reduction | [195] |
Ferulic acid | ATS | High-fat-fed ApoE KO mice and Human mononuclear cell | Reduction of oxidative stress | [202] | |
Mfn1 and Opa1 (+) |
Fish oil | ATS | High-fat-fed ApoE KO mice | Improvement of endothelial dysfunction | [201] |
Mfn1/2 and Opa1 (+) |
Resveratrol | ATS | HUVEC treated with palmitic acid | Improvement of cell viability and reduction of oxidative stress | [200] |
Drp1 (−), Mfn2 (+) | Trimetazidine | PH | Human PASMC | Inhibition of hypoxia-induced cell proliferation | [190] |
Drp1 (−), Mfn2 and Opa1 (+) |
Donepezil | I/R | Wistar rat with I/R injury | Amelioration of apoptosis and mitochondrial dysfunction | [179] |
Calhex231 | HTN | SHR | Inhibition of apoptosis | [203] | |
Drp1 (−), Mfn1 and Opa1 (+) |
Nicorandil | Ischemic HF | Rat with I/R injury | Increased mitochondrial ATP-sensitive potassium channel opening | [206] |
Drp1 (−), Opa1 (+) | Sevoflurane postconditioning | Ischemic HF | Sprague-Dawley rat with I/R injury | Induction of mitophagy and improvement of myocardial ATP production | [181] |
Opa1 (+) | RIPC | I/R | Wistar rat with I/R injury | MI size reduction | [166] |
Irisin | Hypoxia-treated cardiomyocyte | Inhibition of apoptosis | [154] | ||
Melatonin | C57BL/6 with I/R injury | Amelioration of apoptosis and mitochondrial dysfunction | [204] | ||
Paeonol | Diabetic CM | Sprague-Dawley rat cardiomyocytes under high glucose condition | Improvement of cardiomyocyte hypertrophy and interstitial fibrosis | [205] | |
Coenzyme Q10 | ATS | High-fat-fed ApoE KO mice | Inhibition of oxidative stress and promotion of energy metabolism | [207] |
Abbreviations: +—upregulation; −—downregulation (inhibition); ARB—Angiotensin II type I receptor inhibitor; MI—myocardial infarct; HUVEC—human umbilical vein endothelial cell; RIPC—remote ischemic preconditioning; CM—cardiomyopathy; Dox-CM—doxorubicin-associated cardiomyopathy; ATS—Atherosclerosis; HTN—hypertension; HF—Heart failure; SHR—spontaneously hypertensive rat. The table was modified from Yoshihiro et al. [208].